Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight
The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease prevalence and expanding geriatric populations. Advances in diagnostic technologies and rapid-acting therapies are accelerating market adoption. Additionally, the launch of emerging therapies such as Selatogrel (Idorsia Pharmaceuticals and Viatris), FDY-5301 (Faraday Pharmaceuticals), Ziltivekimab (Novo Nordisk), Zalunfiban (CeleCor Therapeutics), and others will further propel the market growth.
LAS VEGAS, May 20, 2026 /PRNewswire/ -- Recently published Acute Myocardial Infarction Market Insights report includes a comprehensive understanding of current treatment practices, acute myocardial infarction emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Acute Myocardial Infarction Market Summary
Discover AMI market CAGR and revenue growth @ https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market
Key Factors Driving the Growth of the Acute Myocardial Infarction Market
Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, said that currently, no approved therapies specifically address the excessive inflammatory response during PCI in STEMI patients. Faraday's FDY-5301 shows promise with its single IV bolus administration, while Kancera's KAND567 also emerges as a potential competitor in this setting.
Acute Myocardial Infarction Market Analysis
Acute Myocardial Infarction Competitive Landscape
Some of the AMI drugs under development include Selatogrel (Idorsia Pharmaceuticals and Viatris), FDY-5301 (Faraday Pharmaceuticals), Dutogliptin (Recardio), Ziltivekimab (Novo Nordisk), Milvexian (Bristol Myers Squibb and Johnson & Johnson Innovative Medicine), Zalunfiban (CeleCor Therapeutics), and others.
Idorsia Pharmaceuticals and Viatris' Selatogrel is a powerful, highly selective, fast-onset, and reversible P2Y12 inhibitor in development for treating acute myocardial infarction (AMI) in individuals at elevated risk of a recurrent event. It is designed for patient self-administration via a subcutaneous autoinjector at the first signs of AMI, producing effects within about 15 minutes that last 4–8 hours. Selatogrel has also been granted Fast Track Designation by the FDA. The company is running a Phase III trial targeting roughly 14,000 participants at risk of recurrent AMI, with completion of enrollment anticipated in 2026.
Faraday Pharmaceuticals' FDY-5301 is a proprietary elemental reducing agent formulated with sodium iodide. Results from a Phase II study in STEMI patients indicated it was well tolerated and showed promising signs of reducing cardiac injury. A Phase III trial (AMI-3) is now underway to evaluate FDY-5301's ability to decrease cardiovascular mortality and heart failure in patients with anterior STEMI undergoing PCI. This study is being conducted under a special protocol agreement with the US FDA.
CeleCor Therapeutics' Zalunfiban is an investigational, next-generation GPIIb/IIIa inhibitor engineered for use by frontline medical teams, including first responders and emergency department personnel. It can be delivered via a subcutaneous injection that fits a full dose into less than 1 milliliter (under ¼ teaspoon). The drug reaches its peak activity in about 15 minutes, and its antiplatelet action fades within roughly two hours, returning to baseline by four hours.
The anticipated launch of these emerging therapies are poised to transform the acute myocardial infarction market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the acute myocardial infarction market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about new drugs in AMI pipeline @ Acute Myocardial Infarction Drugs
Recent Developments in the Acute Myocardial Infarction Market
What is Acute Myocardial Infarction?
Acute Myocardial Infarction (AMI), commonly known as a heart attack, occurs when blood flow to a part of the heart muscle is suddenly blocked, usually by a blood clot forming on a ruptured atherosclerotic plaque inside a coronary artery. Without adequate oxygen-rich blood, the affected portion of the heart muscle becomes damaged or begins to die. This condition often presents with symptoms such as chest pain or pressure, shortness of breath, nausea, sweating, or pain radiating to the arm, jaw, or back. AMI is a medical emergency, and rapid treatment is crucial to restore blood flow, minimize heart muscle damage, and improve the chances of survival.
Acute Myocardial Infarction Epidemiology Segmentation
The acute myocardial infarction epidemiology section provides insights into the historical and current acute myocardial infarction patient pool and forecasted trends for the leading markets. It has been observed that NSTEMI type accounted for a majority of the cases compared to STEMI, i.e., ~75% of the total AMI cases.
The acute myocardial infarction treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Acute Myocardial Infarction Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Acute Myocardial Infarction Market CAGR
13 %
Acute Myocardial Infarction Market Size in 2025
USD 1.6 Billion
Key Acute Myocardial Infarction Companies
Idorsia Pharmaceuticals, Recardio, Kancera, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Faraday Pharmaceuticals, Novo Nordisk, CeleCor Therapeutics, AGEPHA Pharma, Genentech, Amgen, Merck, Regeneron, Sanofi, and others
Key Acute Myocardial Infarction Therapies
Selatogrel, Dutogliptin, KAND567, Milvexian, ProtheraCytes, FDY-5301, Ziltivekimab, Zalunfiban, LODOCO, TNKase, REPATHA, ZONTIVITY, PRALUENT, and others
Scope of the Acute Myocardial Infarction Market Report
Download the report to understand who are the major companies in the AMI space @ Acute Myocardial Infarction Market Analysis
Table of Contents
1
Acute Myocardial Infarction Market Key Insights
2
Acute Myocardial Infarction Market Report Introduction
3
Executive Summary
4
Acute Myocardial Infarction Market Overview at a Glance
4.1
Marketed and Emerging Landscape Analysis (By Phase, RoA, and Molecule Type)
4.2
Market Share Distribution by Therapies (%) in 2024 in the 7MM
4.3
Market Share Distribution by Therapies (%) in 2034 in the 7MM
5
Epidemiology and Market Forecast Methodology
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Risk Factors
7.3
Pathophysiology
7.4
Clinical Classification of Myocardial Infarction
7.5
Diagnosis
7.6
Biomarkers
7.7
Definition of a Prior MI
7.8
WHO definition and diagnostic criteria of MI
8
Treatment and Management
9
Guidelines and Recommendations for MI
10
Epidemiology and Patient Population of AMI in the 7MM
10.1
Key Findings
10.2
Assumptions and Rationale
10.3
Total Incident Cases of AMI in the 7MM
10.4
The United States
10.4.1
Total Incident Cases of AMI in the United States
10.4.2
Type-specific Incident Cases of AMI in the United States
10.4.3
Gender-specific Incident Cases of AMI in the United States
10.5
EU4 and the UK
10.6
Japan
11
Acute Myocardial Infarction Patient Journey
12
Marketed Acute Myocardial Infarction Drugs
12.1
Key Cross Competition
12.2
Colchicine (LODOCO): AGEPHA Pharma
12.2.1
Product Description
12.2.2
Regulatory Milestone
12.2.3
Pivotal Clinical Trial
12.2.4
Other Developmental Activities
12.2.5
Clinical Development
12.2.5.1
Clinical Trials Information
12.2.6
Safety and Efficacy
12.2.7
Analyst Views
12.3
Tenecteplase (TNKase): Genentech
12.4
Evolocumab (REPATHA): Amgen
12.5
Alirocumab (PRALUENT): Regeneron and Sanofi
13
Other Marketed Assets
13.1
Key Cross Competition
13.2
Eplerenone (INSPRA): Pfizer
13.2.1
Product Description
13.2.2
Regulatory Milestone
13.2.3
Pivotal Clinical Trial
13.2.4
Other Developmental Activities
13.2.5
Clinical Development
13.2.5.1
Clinical Trials Information
13.2.6
Safety and Efficacy
13.2.7
Analyst Views
13.2.3
Safety and efficacy
13.3
Clopidogrel bisulfate (PLAVIX): Sanofi-Aventis/Bristol-Myers Squibb
13.4
Ticagrelor (BRILINTA/BRILIQUE): AstraZeneca
13.5
Prasugrel (EFFIENT/EFIENT): Daiichi Sankyo/Eli Lilly and Company
13.6
Candesartan (ATACAND): AstraZeneca/Takeda
13.7
Valsartan (DIOVAN): Novartis
Full list of marketed drugs will be provided in the report
14
Emerging Acute Myocardial Infarction Therapies
14.1
Key Cross Competition
14.2
Selatogrel (ACT-246475): Idorsia Pharmaceuticals and Viatris
14.2.1
Product Description
14.2.2
Other Developmental Activities
14.2.3
Clinical Development
14.2.4
Safety and Efficacy
14.2.5
Analyst View
14.3
Dutogliptin: Recardio
14.4
FDY-5301: Faraday Pharmaceuticals
14.5
Zalunfiban (RUC 4): CeleCor Therapeutics
14.6
Ziltivekimab: Novo Nordisk
14.7
Milvexian: Bristol Myers Squibb and Johnson & Johnson Innovative Medicine
14.8
ProtheraCytes: CellProthera and BioCardia
14.9
KAND567: Kancera
Full list of marketed drugs will be provided in the report
15
Acute Myocardial Infarction Market: 7MM Analysis
15.1
Key Findings
15.2
AMI Market Outlook
15.3
Conjoint Analysis
15.4
Key Market Forecast Assumptions
15.5
Total Market Size of AMI in the 7MM
15.6
United States Acute Myocardial Infarction Market Size
15.6.1
Total Market Size of AMI in the United States
15.6.2
Market Size of AMI by Therapies in the United States
15.7
EU4 and the UK Acute Myocardial Infarction Market Size
15.8
Japan Acute Myocardial Infarction Market Size
16
Acute Myocardial Infarction Market Unmet Needs
17
Acute Myocardial Infarction Market SWOT Analysis
18
KOL Views on AMI
19
Acute Myocardial Infarction Market Access and Reimbursement
19.1
United States
19.2
EU4 and the UK
19.3
Japan
19.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
19.5
Reimbursement Scenario and Key HTA Decisions in AMI
20
Bibliography
21
Acute Myocardial Infarction Market Report Methodology
Related Reports
Myocardial Infarction Market
Myocardial Infarction Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myocardial infarction companies including AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others.
Myocardial Infarction Clinical Trial Analysis
Myocardial Infarction Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myocardial infarction companies, including Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals, among others.
Chronic Heart Failure Market
Chronic Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CHF companies including Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
Congestive Heart Failure Market
Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key congestive heart failure companies, including Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP